Key clinical point: Along with its efficacy as a migraine preventive treatment, fremanezumab demonstrates the potential benefit for reversion from chronic migraine (CM) to episodic migraine (EM).
Major finding: The rates of reversion from CM to EM were higher in patients treated with fremanezumab vs. those treated with placebo, when reversion was defined either as an average of less than 15 headache days per month during the 3-month treatment period (quarterly: 50.5%; P = .108 and monthly: 53.7%; P = .012 vs. placebo: 44.5%) or, more stringently, as less than 15 headache days per month at months 1, 2, and 3 (quarterly: 31.2%; P = .008 and monthly: 33.7%; P = .001 vs. placebo: 22.4%).
Study details: The findings are based on a post hoc analysis of the HALO CM trial. Patients with CM (n=1,088) were randomly assigned to 1 of the 3 treatment groups (fremanezumab quarterly, n=376; fremanezumab monthly, n=379; or placebo, n=375).
Disclosures: The study was funded by Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel. Some study investigators reported being an employee of Teva Branded Pharmaceutical Products R&D, Inc., receiving honoraria from, and/or consulting for Teva Pharmaceuticals.
Source: Lipton RB et al. Headache. 2020 Nov 11. doi: 10.1111/head.13997.